<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905330</url>
  </required_header>
  <id_info>
    <org_study_id>MRX-502</org_study_id>
    <secondary_id>2019-001211-22</secondary_id>
    <nct_id>NCT03905330</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)</brief_title>
  <acronym>MARCH-PFIC</acronym>
  <official_title>MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the investigational treatment (maralixibat) is&#xD;
      safe and effective in pediatric participants with Progressive Familial Intrahepatic&#xD;
      Cholestasis (PFIC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted at multiple sites in North America, Europe, Asia, and South&#xD;
      America.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response as measured by the mean change in pruritus severity as assessed by the Observer rated Itch Reported Outcome (ItchRO [Obs])</measure>
    <time_frame>Between Baseline and Week 15 through 26</time_frame>
    <description>Compare the average before midday (AM) Observer Itch Reported Outcome (ItchRO[Obs]) pruritus severity score between participants on active treatment versus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment response as measured by the mean change in pruritus frequency as assessed by the Observer rated Itch Reported Outcome (ItchRO [Obs])</measure>
    <time_frame>Between Baseline and Week 15 through 26</time_frame>
    <description>Compare the average before midday (AM) Observer Itch Reported Outcome (ItchRO[Obs]) pruritus frequency score between participants on active treatment versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in total serum Bile Acids</measure>
    <time_frame>Between Baseline and Week 26</time_frame>
    <description>Compare normalization or reduction in total serum Bile Acids between participants on active treatment versus placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Progressive Familial Intrahepatic Cholestasis (PFIC)</condition>
  <arm_group>
    <arm_group_label>Maralixibat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maralixibat</intervention_name>
    <description>Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.</description>
    <arm_group_label>Maralixibat</arm_group_label>
    <other_name>Formerly LUM001 and SHP625</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to maralixibat orally twice daily for 26 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent and assent (as applicable) per Institutional Review Board/Ethics&#xD;
             Committee (IRB/EC)&#xD;
&#xD;
          -  Male or female subjects with a body weight ≥ 5.0 kg, who are ≥ 12 months and &lt; 18&#xD;
             years of age at time of baseline&#xD;
&#xD;
          -  Cholestasis as manifested by total sBA ≥ 3× Upper Limit of Normal (ULN) (applies to&#xD;
             primary cohort only)&#xD;
&#xD;
          -  Moderate Pruritus&#xD;
&#xD;
          -  Diagnosis of PFIC based on:&#xD;
&#xD;
               -  Chronic cholestasis as manifested by persistent (&gt;6 months) pruritus, in addition&#xD;
                  to biochemical abnormalities and/or pathological evidence of progressive liver&#xD;
                  disease and&#xD;
&#xD;
               -  Primary Cohort: Subjects with genetic testing results consistent with biallelic&#xD;
                  disease-causing variation in ABCB11 (PFIC2), based on standard of care genotyping&#xD;
&#xD;
               -  Supplemental Cohort: i. Subjects with genetic testing results consistent with&#xD;
                  biallelic disease-causing variation in ATP8B1 (PFIC1), ABCB4 (PFIC3), or TJP2&#xD;
                  (PFIC4), based on standard of care genotyping ii. Subjects with PFIC phenotype&#xD;
                  without a known mutation or with another known mutation not described above or&#xD;
                  with intermittent cholestasis as manifested by fluctuating sBA levelsiii.&#xD;
                  Subjects with PFIC after internal or external biliary diversion surgery or for&#xD;
                  whom internal or external biliary diversion surgery was reversed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Predicted complete absence of bile salt excretion pump (BSEP) function based on the&#xD;
             type of ABCB11 mutation (PFIC2), as determined by a standard of care genotyping&#xD;
             (applies to primary cohort only). Subjects can enter the study in the Supplemental&#xD;
             Cohort (under inclusion criteria 6.ii or 6.iii).&#xD;
&#xD;
          -  Recurrent intrahepatic cholestasis, indicated by a history of sBA levels &lt;3x ULN or&#xD;
             intermittent pruritus (applies to primary cohort only)&#xD;
&#xD;
          -  Current or recent history (&lt;1 year) of atopic dermatitis or other non-cholestatic&#xD;
             diseases associated with pruritus&#xD;
&#xD;
          -  History of surgical disruption of the enterohepatic circulation (applies to primary&#xD;
             cohort only)&#xD;
&#xD;
          -  Chronic diarrhea requiring intravenous fluid or nutritional intervention for the&#xD;
             diarrhea and/or its sequelae at screening or during the 6 months prior to screening&#xD;
&#xD;
          -  Previous or need for imminent liver transplant&#xD;
&#xD;
          -  Decompensated cirrhosis (international normalized ratio [INR] &gt; 1.5, and/or albumin &lt;&#xD;
             30 g/L, history or presence of clinically significant ascites, and/or variceal&#xD;
             hemorrhage, and/or encephalopathy)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or total serum bilirubin (TSB) &gt; 15× ULN at screening&#xD;
&#xD;
          -  Presence of other liver disease&#xD;
&#xD;
          -  Presence of any other disease or condition known to interfere with the absorption,&#xD;
             distribution, metabolism or excretion of drugs, including bile salt metabolism in the&#xD;
             intestine (e.g., inflammatory bowel disease), per Investigator discretion&#xD;
&#xD;
          -  Possibly malignant liver mass on imaging, including screening ultrasound&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Any prior cancer diagnosis (except for in situ carcinoma) within 5 years of the&#xD;
             screening visit (Visit 0)&#xD;
&#xD;
          -  Any known history of alcohol or substance abuse&#xD;
&#xD;
          -  Administration of bile acids or lipid binding resins, or phenylbutyrate during the&#xD;
             screening period&#xD;
&#xD;
          -  Administration of any investigational drug, biologic, or medical device during the&#xD;
             screening period&#xD;
&#xD;
          -  Previous use of an ileal bile acid transporter inhibitor (IBATi)&#xD;
&#xD;
          -  History of non-adherence to medical regimens, unreliability, medical condition, mental&#xD;
             instability or cognitive impairment that, in the opinion of the Investigator or&#xD;
             Sponsor medical monitor, could compromise the validity of informed consent, compromise&#xD;
             the safety of the subject, or lead to nonadherence with the study protocol or&#xD;
             inability to conduct the study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Mirum</last_name>
    <phone>+16506674085</phone>
    <email>clinicaltrials@mirumpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medinfo Mirum</last_name>
    <email>medinfo@mirumpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children Hospital LA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuan-Hao Lin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Rosenthal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medstar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udeme Ekong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advent Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regino Gonzalez-Peralta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine (University of Michigan)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Lopez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ajay Kumar Jain, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University, Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Vittorio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Ovchinsky, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Miethke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Hupertz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Loomes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert H Squires, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kasi Nagraj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VUMC (Vanderbilt University School of Medicine)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynette Gillis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amal Aqul, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas, Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveen K Mittal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Horslen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel D'Agostino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolf-Dietrich Huber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL Cliniques Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne Sokal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente de Senhoras Hospital Sírio-Libanês</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilda Porta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta, Edmonton Clinic Health Academy</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Gilmore, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binita Kamath, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardioinfantil</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Ordoñez Gerrero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 9</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nowenn Laborde, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Gonzales, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Est Hopital, Femme Mère Enfant de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noémie Laverdure, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille, Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand Roquelaure, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Baumann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem - Altalanos Orvostudomanyi Kar (SE AOK)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antal Dezsőfi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Papa Giovanni XXIII / Unità di Pediatria</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo D'Antiga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico bambino Gesu'</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manila Canduso, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de France, Alfred Naccache</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adib Moukarzel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consultario de Joshue David Covarrubias Esquer</name>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshue Covarrubias Esquer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Pomnik Centrum, Zdrowia Dziecka</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Czubkowski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang Kuan Chiou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Koc University Research Center for Translational Medicine (KUTTAM)</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Çiğdem Arikan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deirdre Kelly, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Thompson, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://ghr.nlm.nih.gov/condition/progressive-familial-intrahepatic-cholestasis</url>
    <description>Genetics Home Reference - PFIC</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>US FDA Resources</description>
  </link>
  <link>
    <url>https://mirumpharma.com/</url>
    <description>Mirum Pharmaceuticals homepage</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholestasis</keyword>
  <keyword>Maralixibat</keyword>
  <keyword>Mutation</keyword>
  <keyword>PFIC</keyword>
  <keyword>PFIC2</keyword>
  <keyword>Bile Duct Diseases</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Biliary Tract Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

